Australian ADHD Panel Said To Have Members With Drug Firm Ties
This article was originally published in PharmAsia News
Executive Summary
An Australian newspaper says physicians and others serving on a panel that sets ADHD treatment guidelines have financial connections to several large drug makers. The Daily Telegraph identified seven of the 10 members of the guideline-setting committee who it said received funds or financial help from drug makers such as Eli Lilly, Celltech and Shire Pharmaceuticals, all makers of ADHD drugs the panel was considering. Among the advice in the guidelines is a warning to ignore alternative treatments, such as diet and exercise, on grounds there is little evidence they are effective. (Click here for more